Australia markets open in 6 hours 14 minutes

Pyxis Oncology, Inc. (PYXS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.9750-0.2250 (-7.03%)
As of 01:43PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close3.2000
Open3.1800
Bid2.9400 x 100
Ask3.0000 x 200
Day's range2.9600 - 3.1800
52-week range1.3500 - 6.8500
Volume731,517
Avg. volume577,538
Market cap175.193M
Beta (5Y monthly)1.34
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 89,530 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 111,913 shares of Pyxis Oncology’s common stock to five newly hir

  • GlobeNewswire

    Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

    BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (Na

  • GlobeNewswire

    Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

    BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Thursday, June 6, 2024 at 9:00 AM Eastern Time at the Jefferies Global Healthcare Conference in New York City, where members of management will also host investor one-on-one meetings. A